Jane S Hankins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9307282/publications.pdf

Version: 2024-02-01

228	4,497	126907	144013
papers	citations	33 h-index	57 g-index

240	240	240	4708
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety of maximal cardiopulmonary exercise testing in individuals with sickle cell disease: a systematic review. British Journal of Sports Medicine, 2022, 56, 764-769.	6.7	2
2	Nocturnal Enuresis in Sickle Cell: Sociodemographic, Medical, and Quality of Life Factors. Journal of Pediatric Psychology, 2022, 47, 75-85.	2.1	2
3	Hepatic Iron Quantification Using a <scp>Freeâ€Breathing 3D</scp> Radial Gradient Echo Technique and Validation With a <scp>2D</scp> Biopsyâ€Calibrated <scp>R₂</scp>[*] Relaxometry Method. Journal of Magnetic Resonance Imaging, 2022, 55, 1407-1416.	3.4	6
4	Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country. BMC Health Services Research, 2022, 22, 42.	2.2	6
5	Neurocognitive risk in sickle cell disease: Utilizing neuropsychology services to manage cognitive symptoms and functional limitations. British Journal of Haematology, 2022, 197, 260-270.	2.5	7
6	Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. American Journal of Hematology, 2022, 97, 603-612.	4.1	25
7	Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists. Thrombosis Research, 2022, 211, 133-139.	1.7	2
8	Adaptive Functioning in Children and Adolescents With Sickle Cell Disease. Journal of Pediatric Psychology, 2022, 47, 939-951.	2.1	2
9	Fetal hemoglobin modulates neurocognitive performance in sickle cell anemiaâœ°,âœ°âœ°. Current Research in Translational Medicine, 2022, 70, 103335.	1.8	3
10	Bridging the implementation gap in medication adherence. If you build it, will they come?. British Journal of Haematology, 2022, 196, 17-18.	2.5	2
11	Neurocognitive functioning in preschool children with sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29531.	1.5	7
12	Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease. Quality of Life Research, 2022, 31, 2729-2738.	3.1	2
13	Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. Blood Advances, 2022, 6, 4461-4470.	5.2	5
14	Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixaforâ€mobilized patients with sickle cell disease. British Journal of Haematology, 2022, 198, 740-744.	2.5	8
15	Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry. Cancer Research, 2021, 81, 2556-2565.	0.9	24
16	Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia. Blood Advances, 2021, 5, 89-98.	5.2	6
17	Quantitative Susceptibility Mapping Using a Multispectral Autoregressive Moving Average Model to Assess Hepatic Iron Overload. Journal of Magnetic Resonance Imaging, 2021, 54, 721-727.	3.4	5
18	Newborn Genetic Screening for Blood Disorders. , 2021, , 93-112.		0

#	Article	IF	Citations
19	Cognitive performance as a predictor of healthcare transition in sickle cell disease. British Journal of Haematology, 2021, 192, 1082-1091.	2.5	13
20	Sickle cell disease and ventricular myocardial strain: A systematic review. Pediatric Blood and Cancer, 2021, 68, e28973.	1.5	3
21	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Advances, 2021, 5, 2403-2411.	5.2	24
22	Gabapentin for acute pain in sickle cell disease: A randomized doubleâ€blinded placeboâ€controlled phase II clinical trial. EJHaem, 2021, 2, 327-334.	1.0	3
23	What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study. British Journal of Haematology, 2021, 194, 463-468.	2.5	6
24	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	2.5	7
25	Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results. British Journal of Haematology, 2021, 194, 469-473.	2.5	1
26	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. Blood Advances, 2021, 5, 2839-2851.	5.2	14
27	Transition care continuity promotes longâ€term retention in adult care among young adults with sickle cell disease. Pediatric Blood and Cancer, 2021, 68, e29209.	1.5	5
28	Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. British Journal of Haematology, 2021, 195, 256-266.	2.5	30
29	Effects of hydroxyurea on brain function in children with sickle cell anemia. Pediatric Blood and Cancer, 2021, 68, e29254.	1.5	14
30	Patientâ€reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. American Journal of Hematology, 2021, 96, 1396-1406.	4.1	15
31	Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia. Experimental Biology and Medicine, 2021, 246, 2473-2479.	2.4	4
32	Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease. Vaccines, 2021, 9, 860.	4.4	2
33	American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Advances, 2021, 5, 3668-3689.	5.2	38
34	Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 629-634.	1.3	55
35	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. Haematologica, 2021, 106, 1749-1753.	3.5	11
36	Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance. JAMA Network Open, 2021, 4, e2128971.	5.9	9

#	Article	IF	Citations
37	Improving Outcomes for Patients With Sickle Cell Disease in the United States. JAMA Health Forum, 2021, 2, e213467.	2.2	17
38	Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS ONE, 2021, 16, e0258638.	2.5	13
39	Empirically Derived Profiles of Health-Related Quality of Life in Youth and Young Adults with Sickle Cell Disease. Journal of Pediatric Psychology, 2021, 46, 293-303.	2.1	9
40	Pain in Youth With Sickle Cell Disease. Clinical Journal of Pain, 2021, 37, 43-50.	1.9	5
41	Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2021, 43, e19-e25.	0.6	3
42	Association of Thrombospondin-1 Gene Polymorphism with Elevated Tricuspid Regurgitant Velocity in Sickle Cell Anemia. Blood, 2021, 138, 2027-2027.	1.4	0
43	Optimization of Autologous Hematopoietic Progenitor Stem Cell Apheresis Collection from Plerixafor-Mobilized Patients with Sickle Cell Disease. Blood, 2021, 138, 1770-1770.	1.4	0
44	Social Determinants of Health and Neurocognitive Functioning in Sickle Cell Disease. Blood, 2021, 138, 2030-2030.	1.4	0
45	Vitamin A and D Levels Correlate with Outcomes Following Acute Parvovirus B19 Infection in Children with Sickle Cell Disease. Blood, 2021, 138, 4181-4181.	1.4	0
46	Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. BMJ Open, 2021, 11, e050880.	1.9	18
47	Successful HPV Vaccination in Adolescents with Sickle Cell Disease Following a Quality Improvement Bundle Intervention. Blood, 2021, 138, 914-914.	1.4	2
48	Vitamin D Levels: Associations with Acute Pain Events and Self-Reported Pain in Children with Sickle Cell Disease. Blood, 2021, 138, 3089-3089.	1.4	0
49	Prevalence of High BMI Status in Adults with Sickle Cell Disease. Blood, 2021, 138, 2039-2039.	1.4	0
50	Reduced Intensity Hematopoietic Cell Transplantation Improves Cerebral Hemodynamics in Children with Sickle Cell Disease. Blood, 2021, 138, 125-125.	1.4	0
51	Assessment of Cardiac Abnormalities in Sickle Cell Disease Patients Using Cardiac Magnetic Resonance Imaging (CMR). Blood, 2021, 138, 3110-3110.	1.4	4
52	Cost Analysis of ACUTE Care Resource Utilization Among Individuals with Sickle Cell Disease in a Middle-Income Country. Blood, 2021, 138, 2987-2987.	1.4	0
53	High Rate of Recurrent Venous Thromboembolism Is Children with Sickle Cell Disease and History of VTE: Analysis of the Trinetx Research Network Database. Blood, 2021, 138, 778-778.	1.4	0
54	Implementation and Preliminary Effectiveness of mHealth Apps for Improving Sickle Cell Disease Care during COVID-19: A Mixed-Methods Evaluation. Blood, 2021, 138, 3038-3038.	1.4	0

#	Article	IF	Citations
55	Impact of Gaps in Care during Adult Care Transfer in Sickle Cell Disease. Blood, 2021, 138, 2992-2992.	1.4	0
56	Academic Performance of Children With Sickle Cell Disease in the United States: A Meta-Analysis. Frontiers in Neurology, 2021, 12, 786065.	2.4	12
57	Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. Children, 2021, 8, 1200.	1.5	2
58	Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination. Genetics in Medicine, 2020, 22, 232-233.	2.4	10
59	The Adolescent and Caregiver Sickle Cell Disease Self-management Skills Checklist: Preliminary Reliability and Validity. Journal of Pediatric Hematology/Oncology, 2020, 42, 12-19.	0.6	5
60	Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. Hematology, 2020, 25, 229-240.	1.5	3
61	A metaâ€analysis of toxicities related to hydroxycarbamide dosing strategies. EJHaem, 2020, 1, 235-238.	1.0	1
62	Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Advances, 2020, 4, 4463-4473.	5.2	23
63	Tackling adherence in sickle cell disease with mHealth. Lancet Haematology,the, 2020, 7, e713-e714.	4.6	5
64	A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data. Blood Advances, 2020, 4, 4347-4357.	5.2	9
65	A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. Annals of Emergency Medicine, 2020, 76, S64-S72.	0.6	22
66	The Sickle Cell Pro-Inflammatory Response to Interval Testing Study (SPRINTS) in children and young adults with sickle cell anemia â€“ Study design and methodological strategies. Contemporary Clinical Trials Communications, 2020, 20, 100668.	1.1	2
67	Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care. JAMA Network Open, 2020, 3, e206016.	5.9	30
68	Vaccine Design Informed by Virus-Induced Immunity. Viral Immunology, 2020, 33, 342-350.	1.3	2
69	Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28250.	1.5	8
70	Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. Blood, 2020, 136, 623-626.	1.4	26
71	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica, 2020, 105, e497.	3.5	29
72	Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet Journal of Rare Diseases, 2020, 15, 178.	2.7	21

#	Article	IF	Citations
73	Attention difficulties are associated with lower engagement in adult care amongst youth with sickle cell disease. British Journal of Haematology, 2020, 189, e27-e30.	2.5	4
74	Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell disease. British Journal of Haematology, 2020, 189, 1192-1203.	2.5	23
75	Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial. Blood, 2020, 136, 5-6.	1.4	3
76	Using Machine Learning to Predict Early Onset Acute Organ Failure in Critically Ill Intensive Care Unit Patients With Sickle Cell Disease: Retrospective Study. Journal of Medical Internet Research, 2020, 22, e14693.	4.3	9
77	Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. JMIR MHealth and UHealth, 2020, 8, e14884.	3.7	38
78	Web-Based Technology to Improve Disease Knowledge Among Adolescents With Sickle Cell Disease: Pilot Study. JMIR Pediatrics and Parenting, 2020, 3, e15093.	1.6	13
79	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. JMIR Research Protocols, 2020, 9, e16319.	1.0	19
80	High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. Haematologica, 2020, 106, 295-298.	3.5	9
81	Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease. Blood, 2020, 136, 33-33.	1.4	1
82	Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry. Blood, 2020, 136, 3-3.	1.4	0
83	Food Deserts Are Associated with Acute Care Utilization Among Preschool Children with Sickle Cell Disease. Blood, 2020, 136, 19-19.	1.4	0
84	Fetal Hemoglobin Mediates the Effect of Beta Globin Gene Polymorphisms on Neurocognitive Functioning in Sickle Cell Disease. Blood, 2020, 136, 23-24.	1.4	0
85	Sex Based Differences in Sickle Cell Disease. Blood, 2020, 136, 37-37.	1.4	0
86	GSTM1 and Liver Iron Content in Children with Sickle Cell Anemia and Iron Overload. Journal of Clinical Medicine, 2019, 8, 1878.	2.4	4
87	Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease. Journal of Surgical Research, 2019, 242, 336-341.	1.6	4
88	Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates. Pediatric Blood and Cancer, 2019, 66, e27717.	1.5	9
89	Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica, 2019, 104, e385-e387.	3.5	26
90	Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura. Pediatric Blood and Cancer, 2019, 66, e27737.	1.5	16

#	Article	IF	Citations
91	Autoregressive moving average modeling for hepatic iron quantification in the presence of fat. Journal of Magnetic Resonance Imaging, 2019, 50, 1620-1632.	3.4	9
92	Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results. Blood Advances, 2019, 3, 1476-1488.	5.2	10
93	End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Advances, 2019, 3, 3982-4001.	5.2	51
94	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematology,the, 2019, 6, e585-e596.	4.6	128
95	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal, 2019, 19, 305-314.	2.0	9
96	The Case for Pharmacogeneticsâ€Guided Prescribing of Codeine in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1300-1302.	4.7	12
97	Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. American Journal of Hematology, 2019, 94, E27-E29.	4.1	19
98	Ultrashort echo time imaging for quantification of hepatic iron overload: Comparison of acquisition and fitting methods via simulations, phantoms, and in vivo data. Journal of Magnetic Resonance Imaging, 2019, 49, 1475-1488.	3.4	6
99	Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology, 2019, 24, 189-198.	1.5	42
100	A program of transition to adult care for sickle cell disease. Hematology American Society of Hematology Education Program, 2019, 2019, 496-504.	2.5	37
101	A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. JMIR MHealth and UHealth, 2019, 7, e13452.	3.7	16
102	Neurocognitive Impairment Predicts Poor Transition Outcomes Among Patients with Sickle Cell Disease. Blood, 2019, 134, 519-519.	1.4	0
103	Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia. Blood, 2019, 134, 2290-2290.	1.4	0
104	Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor. Blood, 2019, 134, 1964-1964.	1.4	0
105	Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study. Blood, 2019, 134, 1002-1002.	1.4	0
106	Transition Continuity Promotes Long-Term Retention in Adult Care Among Young Adults with Sickle Cell Disease. Blood, 2019, 134, 4676-4676.	1.4	1
107	Evaluation of Factors Influencing Health Literacy in Adolescents and Adults with Sickle Cell Disease. Blood, 2019, 134, 2110-2110.	1.4	1
108	Longitudinal Effect of Hydroxyurea Therapy on Left Ventricular Diastolic Function in Sickle Cell Anemia. Blood, 2019, 134, 1006-1006.	1.4	0

#	Article	IF	Citations
109	Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. Hematology, 2018, 23, 683-691.	1.5	23
110	Automated vessel exclusion technique for quantitative assessment of hepatic iron overload by â€MRI. Journal of Magnetic Resonance Imaging, 2018, 47, 1542-1551.	3.4	5
111	Fast quantitative parameter maps without fitting: Integration yields accurate monoâ€exponential signal decay rates. Magnetic Resonance in Medicine, 2018, 79, 2978-2985.	3.0	4
112	State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease. Paediatric Drugs, 2018, 20, 29-42.	3.1	16
113	Pediatric to adult care coâ€location transitional model for youth with sickle cell disease. American Journal of Hematology, 2018, 93, E30-E32.	4.1	16
114	Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. Haematologica, 2018, 103, e50-e54.	3.5	25
115	Ventricular global longitudinal strain is altered in children with sickle cell disease. British Journal of Haematology, 2018, 183, 796-806.	2.5	14
116	The sickle cell disease implementation consortium: Translating evidenceâ€based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395.	4.1	52
117	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatric Blood and Cancer, 2018, 65, e27228.	1.5	57
118	Acute kidney injury during parvovirus B19â€induced transient aplastic crisis in sickle cell disease. American Journal of Hematology, 2018, 93, E198.	4.1	6
119	Efficacy of a Health Care Transition Program for Patients with Sickle Cell Disease. Blood, 2018, 132, 5820-5820.	1.4	2
120	Data Access and Interactive Visualization of Whole Genome Sequence of Sickle Cell Patients within the St. Jude Cloud. Blood, 2018, 132, 723-723.	1.4	2
121	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	1.4	3
122	Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review. Journal of Medical Internet Research, 2018, 20, e10940.	4.3	119
123	Fetal Hemoglobin Level during Hydroxyurea Therapy Varies By Neighborhood. Blood, 2018, 132, 2221-2221.	1.4	0
124	Insulin-like Growth Factor Binding Protein-3 (IGFBP3) Induces Fetal Hemoglobin in Hematopoietic Stem and Progenitor Cells from Patients with Sickle Cell Anemia. Blood, 2018, 132, 722-722.	1.4	0
125	Accurate Prediction of RH Genotypes Using Whole Genome Sequencing Data. Blood, 2018, 132, 2332-2332.	1.4	0
126	Interruption in Care Continuity during Healthcare Transition from Pediatric to Adult Care Increases Acute Care Utilization. Blood, 2018, 132, 2226-2226.	1.4	1

#	Article	IF	Citations
127	Children with Sickle Cell Anemia and APOL1 Gene Variants Develop Albuminuria Early in Life. Blood, 2018, 132, 2377-2377.	1.4	1
128	Reduced Plasmodium Falciparum Growth in Erythrocytes Is Associated with Fetal Hemoglobin Expression. Blood, 2018, 132, 1067-1067.	1.4	0
129	Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. Sleep and Breathing, 2017, 21, 697-701.	1.7	14
130	The impact of the UGT1A1*60 allele on bilirubin serum concentrations. Pharmacogenomics, 2017, 18, 5-16.	1.3	4
131	Can multi-slice or navigator-gated R2* MRI replace single-slice breath-hold acquisition for hepatic iron quantification?. Pediatric Radiology, 2017, 47, 46-54.	2.0	3
132	Quantitative ultrashort echo time imaging for assessment of massive iron overload at 1.5 and 3 Tesla. Magnetic Resonance in Medicine, 2017, 78, 1839-1851.	3.0	50
133	The clinical severity of hemoglobin S/Black (^AÎ³Î²)⁰â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26596.	1.5	5
134	Radial Ultrashort TE Imaging Removes the Need for Breath-Holding in Hepatic Iron Overload Quantification by R2* MRI. American Journal of Roentgenology, 2017, 209, 187-194.	2.2	12
135	Saccharomyces cerevisiae -derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease. Vaccine, 2017, 35, 3615-3620.	3.8	18
136	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology, 2017, 92, 1333-1339.	4.1	66
137	Pediatric to Adult Care Transition: Perspectives of Young Adults With Sickle Cell Disease. Journal of Pediatric Psychology, 2017, 42, 1016-1027.	2.1	27
138	Removal of Arterial Vessel Contributions in Susceptibility-Weighted Images for Quantification of Normalized Visible Venous Volume in Children with Sickle Cell Disease. Journal of Healthcare Engineering, 2017, 2017, 1-8.	1.9	1
139	A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring. Pediatric Quality & Safety, 2017, 2, e024.	0.8	6
140	Using qualitative perspectives of adolescents with sickle cell disease and caregivers to develop healthcare transition programming.. Clinical Practice in Pediatric Psychology, 2017, 5, 319-329.	0.3	7
141	Effects of Hydroxyurea (HU) on Neurocognitive Performance in Children with Sickle Cell Disease: A Prospective Trial. Blood, 2017, 130, 760-760.	1.4	3
142	Does fat suppression via chemically selective saturation affect R2*-MRI for transfusional iron overload assessment? A clinical evaluation at 1.5T and 3T. Magnetic Resonance in Medicine, 2016, 76, 591-601.	3.0	25
143	Birth Prevalence of Sickle Cell Trait and Sickle Cell Disease in Shelby County, TN. Pediatric Blood and Cancer, 2016, 63, 1054-1059.	1.5	5
144	Future Perspectives for the Treatment of Sickle Cell Anemia. , 2016, , 399-429.		4

#	Article	IF	Citations
145	Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. British Journal of Haematology, 2016, 175, 331-338.	2.5	26
146	Barriers and facilitators to research participation among adults, and parents of children with sickle cell disease: A transâ€regional survey. American Journal of Hematology, 2016, 91, E461-2.	4.1	8
147	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics, 2016, 138, .	2.1	71
148	Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study. Clinical Trials, 2016, 13, 409-416.	1.6	14
149	Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Experimental Biology and Medicine, 2016, 241, 749-754.	2.4	21
150	Distance from an Urban Sickle Cell Center and its Effects on Routine Healthcare Management and Rates of Hospitalization. Hemoglobin, 2016, 40, 10-15.	0.8	6
151	Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial. Blood, 2016, 128, 1274-1274.	1.4	3
152	Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the Î²-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production. Blood, 2016, 128, 125-125.	1.4	0
153	Prevention of conversion to abnormal transcranial <scp>D</scp>oppler with hydroxyurea in sickle cell anemia: A <scp>P</scp>hase III international randomized clinical trial. American Journal of Hematology, 2015, 90, 1099-1105.	4.1	59
154	Paroxysmal cold hemoglobinuria due to an IgA Donathâ€“Landsteiner antibody. Pediatric Blood and Cancer, 2015, 62, 2044-2046.	1.5	5
155	Comparing segmented ASL perfusion of vascular territories using manual versus semiautomated techniques in children with sickle cell anemia. Journal of Magnetic Resonance Imaging, 2015, 41, spcone-spcone.	3.4	0
156	The ASPHO 2015 Distinguished Career Award Goes to Dr. Winfred C. Wang, MD. Pediatric Blood and Cancer, 2015, 62, 19-20.	1.5	0
157	Severe Autoimmune Hemolytic Anemia in an Infant Caused by Warm-reactive IGM and IGA Autoantibodies. Journal of Pediatric Hematology/Oncology, 2015, 37, 468-471.	0.6	5
158	Comparing segmented ASL perfusion of vascular territories using manual versus semiautomated techniques in children with sickle cell anemia. Journal of Magnetic Resonance Imaging, 2015, 41, 439-446.	3.4	8
159	Prevalence of Vitamin D Deficiency in Sickle Cell Disease: A Systematic Review. PLoS ONE, 2015, 10, e0119908.	2.5	48
160	Streptococcus pneumoniae Translocates into the Myocardium and Forms Unique Microlesions That Disrupt Cardiac Function. PLoS Pathogens, 2014, 10, e1004383.	4.7	183
161	Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. European Journal of Haematology, 2014, 93, 377-383.	2.2	25
162	Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatric Blood and Cancer, 2014, 61, 2031-2036.	1.5	51

#	Article	IF	Citations
163	From Infancy to Adolescence. Medicine (United States), 2014, 93, e215.	1.0	59
164	Genetic Education and Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, 572-577.	0.6	13
165	Transition From Pediatric to Adult Care in Sickle Cell Disease: Perspectives on the Family Role. Journal of Pediatric Nursing, 2014, 29, 158-167.	1.5	34
166	Assessment of Sleep-Related Disorders in Children With Sickle Cell Disease. Hemoglobin, 2014, 38, 244-251.	0.8	31
167	Evaluation of SWI in Children with Sickle Cell Disease. American Journal of Neuroradiology, 2014, 35, 1016-1021.	2.4	10
168	Elevated Tricuspid Regurgitation Jet Velocity in Patients with Sickling and Non-Sickling Hemolytic Anemias: Prevalence and Correlates. Blood, 2014, 124, 4906-4906.	1.4	0
169	A Medical Home Model with Overlap of Pediatric and Adult Care Mitigates the Upsurge in Health Care Utilization Post-Transfer to Adult Care in Sickle Cell Disease. Blood, 2014, 124, 443-443.	1.4	0
170	Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia. Blood, 2014, 124, 89-89.	1.4	0
171	High Failure Rate with Brigance Developmental Screening in 3 Year-Old Children with Sickle Cell Disease. Blood, 2014, 124, 4926-4926.	1.4	0
172	Automated T₂* measurements using supplementary field mapping to assess cardiac iron content. Journal of Magnetic Resonance Imaging, 2013, 38, 441-447.	3.4	4
173	Trends in transfusion burden among long-term survivors of childhood hematological malignancies. Leukemia and Lymphoma, 2013, 54, 1719-1723.	1.3	19
174	Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. American Journal of Hematology, 2013, 88, 116-119.	4.1	85
175	The Clinical and Laboratory Spectrum of Hb C [Î²6(A3)Gluâ†'Lys,GAG>AAG] Disease. Hemoglobin, 2013, 37, 16-25.	0.8	6
176	Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. British Journal of Haematology, 2013, 161, 402-405.	2.5	40
177	The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. British Journal of Haematology, 2013, 161, 852-860.	2.5	129
178	Effects of adenotonsillectomy on polysomnographic parameters in children with sickle cell disease. Pediatric Blood and Cancer, 2013, 60, E26-8.	1.5	21
179	Phenocopy of Warfarin Syndrome in an Infant Born to a Mother With Sickle Cell Anemia and Severe Transfusional Iron Overload. Journal of Pediatric Hematology/Oncology, 2013, 35, e265-e268.	0.6	2
180	Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program. PLoS ONE, 2013, 8, e72077.	2.5	32

#	Article	IF	Citations
181	Exploring Family Communication About Sickle Cell Disease in Adolescence. Journal of Pediatric Oncology Nursing, 2012, 29, 323-336.	1.5	13
182	A Transition Pilot Program for Adolescents With Sickle Cell Disease. Journal of Pediatric Health Care, 2012, 26, e45-e49.	1.2	69
183	Parental Stress in Families of Children with a Genetic Disorder/Disability and the Resiliency Model of Family Stress, Adjustment, and Adaptation. Issues in Comprehensive Pediatric Nursing, 2012, 35, 24-44.	0.6	54
184	The impact of preparation and support procedures for children with sickle cell disease undergoing MRI. Pediatric Radiology, 2012, 42, 1223-1228.	2.0	24
185	Simultaneous field and R mapping to quantify liver iron content using autoregressive moving average modeling. Journal of Magnetic Resonance Imaging, 2012, 35, 1125-1132.	3.4	24
186	Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. British Journal of Haematology, 2012, 156, 259-264.	2.5	97
187	Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. British Journal of Haematology, 2012, 157, 240-248.	2.5	26
188	Is sickle cell disease the same everywhere?. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 178-179.	0.7	1
189	Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatric Nephrology, 2011, 26, 1285-1290.	1.7	103
190	Neurocognitive screening with the Brigance Preschool screenâ€¦ in 3â€yearâ€old children with sickle cell disease. Pediatric Blood and Cancer, 2011, 56, 620-624.	1.5	22
191	The Impact of Hydroxyurea Therapy on the Prevalence of Retinopathy in a Pediatric Sickle Cell Cohort. Blood, 2011, 118, 1057-1057.	1.4	0
192	Cognitive Dysfunction Occurs In Children with Sickle Cell Anemia without Cerebral Ischemic Insult or Vasculopathy. Blood, 2011, 118, 1076-1076.	1.4	0
193	Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overload. Pediatric Radiology, 2010, 40, 1360-1367.	2.0	55
194	Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. European Journal of Haematology, 2010, 85, 51-57.	2.2	30
195	Should my child participate in this research study?. Pediatric Blood and Cancer, 2010, 55, 12-13.	1.5	3
196	Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition. Pediatric Blood and Cancer, 2010, 55, 495-500.	1.5	49
197	The diagnostic dilemma of congenital unstable hemoglobinopathies. Pediatric Blood and Cancer, 2010, 55, 1393-1395.	1.5	21
198	Exploring Parent-Sibling Communication in Families of Children with Sickle Cell Disease. Issues in Comprehensive Pediatric Nursing, 2010, 33, 101-123.	0.6	17

#	Article	IF	Citations
199	â€œIt's Our Jobâ€: Qualitative Study of Family Responses to Ableism. Intellectual and Developmental Disabilities, 2010, 48, 245-258.	1.1	30
200	Hydroxyurea Therapy Reduces Mortality Among Children with Sickle Cell Disease. Blood, 2010, 116, 843-843.	1.4	6
201	Microarray Analysis of Erythroid Gene Expression In Sickle Cell Anemia Patients Treated with Hydroxyurea.. Blood, 2010, 116, 1623-1623.	1.4	1
202	Characterization of HbF Decline In Compound Heterozygotes for HbS and Deletional Hereditary Persistence of Fetal Hemoglobin. Blood, 2010, 116, 1626-1626.	1.4	2
203	Decision Analysis of Treatment Strategies in Children With Severe Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2009, 31, 873-878.	0.6	17
204	Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and betaâ€thalassemia. American Journal of Hematology, 2009, 84, 328-334.	4.1	14
205	Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients. American Journal of Hematology, 2009, 84, 603-606.	4.1	15
206	Arterial spinâ€labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatric Blood and Cancer, 2009, 52, 85-91.	1.5	39
207	The painful face of poverty. Pediatric Blood and Cancer, 2009, 52, 157-158.	1.5	15
208	Simultaneous acute splenic sequestration and transient aplastic crisis in children with sickle cell disease. Pediatric Blood and Cancer, 2009, 53, 479-481.	1.5	19
209	Pharmacotherapy in sickle cell disease â€“ state of the art and future prospects. British Journal of Haematology, 2009, 145, 296-308.	2.5	35
210	Sickle-cell disease: an ounce of prevention, a pound of cure. Lancet, The, 2009, 374, 1308-1310.	13.7	10
211	R2* magnetic resonance imaging of the liver in patients with iron overload. Blood, 2009, 113, 4853-4855.	1.4	311
212	Glomerular Hyperfiltration and Microalbuminuria in Children with Sickle Cell Anemia.. Blood, 2009, 114, 263-263.	1.4	5
213	Genetic Predictors of Hydroxyurea Response in Children with Sickle Cell Disease.. Blood, 2009, 114, 820-820.	1.4	1
214	Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood and Cancer, 2008, 50, 293-297.	1.5	81
215	Biloma and pneumobilia in sickle cell disease. Pediatric Blood and Cancer, 2008, 51, 288-290.	1.5	7
216	The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. British Journal of Haematology, 2008, 142, 94-99.	2.5	50

#	Article	IF	Citations
217	CHEMICAL AND FUNCTIONAL ANALYSIS OF GENERIC HYDROXYUREA FORMULATIONS. Pediatric Hematology and Oncology, 2008, 25, 423-429.	0.8	6
218	Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatric Blood and Cancer, 2007, 48, 705-710.	1.5	75
219	Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. British Journal of Haematology, 2007, 140, 071107175539001-???.	2.5	33
220	R* Magnetic Resonance Imaging (MRI) of the Liver for Patients with Iron Overload.. Blood, 2007, 110, 2670-2670.	1.4	0
221	Cardiac T2* Magnetic Resonance Imaging (MRI) in Iron Overload and Ventricular Diastolic Function.. Blood, 2007, 110, 2676-2676.	1.4	1
222	Phase I Study of Combination Treatment with Hydroxyurea and Magnesium Pidolate in Children with Sickle Cell Anemia.. Blood, 2006, 108, 686-686.	1.4	0
223	Chronic Transfusion Therapy for Children With Sickle Cell Disease and Recurrent Acute Chest Syndrome. Journal of Pediatric Hematology/Oncology, 2005, 27, 158-161.	0.6	52
224	Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 2005, 106, 2269-2275.	1.4	251
225	THE INFLUENCE OF TRAUMATIC LUMBAR PUNCTURE AND TIMING OF INTRATHECAL THERAPY ON OUTCOME OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA. Pediatric Hematology and Oncology, 2005, 22, 483-488.	0.8	20
226	Therapeutic Intervention and Decision-Making by Parents of Children with Severe Sickle Cell Anemia.. Blood, 2005, 106, 3193-3193.	1.4	0
227	Thrombocytosis in an Infant With High Thrombopoietin Concentrations. Journal of Pediatric Hematology/Oncology, 2004, 26, 142-145.	0.6	6
228	Therapeutic Intervention and Decision-Making by Primary Caregivers of Children with Severe Sickle Cell Anemia.. Blood, 2004, 104, 1661-1661.	1.4	0